*February 2022*
Open Questions Around First-Line Treatment for EGFR Mutant Lung Cancers, Dr Helena Yu, presenter
Acquired Resistance to EGFR TKIs, Dr. Katerina Politi, presenter
Histological transformation and off target mechanisms are frequently identified on disease progression for patients with EGFRmutant lung cancer treated with first-line osimertinib, Dr. Noura Choudhury, presenter
What Is the Current and Future Role of IO in EGFR and Other Driver Mutation-Positive NSCLC? Dr. Jonathan Riess, presenter
Investigating Osimertinib Efficacy in Patients with Tumors Harboring the Uncommon EGFR Exon Deletion 19 Mutation L747-A750>P, Dr. Michael Grant, presenter
